News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Leadership in Proteasome Inhibition Highlighted in Relapsed/Refractory Multiple Myeloma At IMW Meeting



5/5/2011 10:22:01 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported results from three studies in relapsed multiple myeloma (MM). Two of the studies examined the use of VELCADE® (bortezomib) for Injection; the third study presents clinical data on MLN9708, the first investigational oral proteasome inhibitor.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES